Therapy for chronic migraine — a condition that’s been notoriously difficult-to-treat and which often leads to significant direct and indirect health care costs — has been upended with the recent approval of three injectable monoclonal antibody products in a new preventive medication class that’s significantly more effective than older preventive migraine drugs, a researcher says.
- People on the Move
- Medicare and Medicaid
- Datapoint, Medicare and Medicaid
- Abstract, Health Plans
- Datapoint, Drug Benefits, Medicare and Medicaid